Each Friday, we provide an update on the current live tracking portfolio (as of the previous day’s closing prices), a summary of the last week of trading activity, and updates on any significant developments among the companies we have positions in.
In this week’s issue of The Big Secret On Wall Street, we perform a brief market analysis following the Fed’s rate cuts and a comprehensive portfolio review on four of our holdings as well as offering actions to take.
In the May 9 Distressed Investing report “Cracking The Code,” we recommended purchasing Green Plains’ 2.25% bonds maturing March 15, 2027. We now recommend selling those bonds. In May, when we recommended them, the bonds were trading at $785, which equated to an annual return of just over 16%. We suggested pairing each bond with
Today’s Trading Club alert gives our portfolio exposure to a long-term global safe haven and unloads shares of an energy company who faces political uncertainty.
In the future, historians will date the beginning of America’s Second Civil War to the fall of 2025 – in part because of the shootings of Donald Trump and Charlie Kirk, but also because of the big lie around Social Security.
Yesterday, aTyr Pharma (Nasdaq: ATYR) reported that its Phase 3 trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint. The study’s results were doomed by a much higher-than-expected placebo effect, making it impossible for efzofitimod to attain the statistically significant differentiation relative to placebo needed for the trial’s success. Shares of aTyr
By investing in forever stocks in the small-cap space you massively outperform the market. Now the million-dollar question is how to find these kinds of companies. As our guest writer today explains: You start by using a stock screener.
Today, Porter compares different ways to build ultra-low volatility portfolios and unveils a new “Lindy” index.